ICG-001 (PRI-724 isomer) (CAS: 780757-88-2) is a small-molecule inhibitor of the Wnt signaling pathway, developed by Prism Pharmaceuticals for the treatment of various cancers, such as liver cancer and colorectal cancer. The Wnt signaling pathway plays a critical role in cell proliferation and differentiation.
Chemical name: (1Z)-N-(1-(3,5-bis(trifluoromethyl)phenyl)-4-oxo-1,3-dihydroindol-2-ylidene)propan-1-amine
Molecular formula: C18H14F6N2O
Formula weight: 426.31 g/mol
CAS No: 780757-88-2
Top ten keywords from Google:
Synonyms:
Health benefits of this product: ICG-001 has shown potential in preclinical and clinical studies for the treatment of various cancers, particularly liver cancer and colorectal cancer. It works by inhibiting the activity of beta-catenin, which is involved in the Wnt signaling pathway. By blocking these receptors, ICG-001 can potentially induce apoptosis and inhibit tumor growth.
Potential effects: ICG-001 has demonstrated efficacy in reducing tumor growth and inducing remission in liver cancer and colorectal cancer in preclinical and clinical studies. It has also shown potential in combination with other anti-cancer agents, such as chemotherapy and radiation therapy. However, more research is needed to determine its full potential and efficacy in different types of cancers.
Product mechanism: ICG-001 inhibits the activity of beta-catenin, which is a key mediator of the Wnt signaling pathway involved in cell proliferation and differentiation. Abnormal activation of this pathway is associated with various cancers, particularly liver cancer and colorectal cancer. As a small-molecule inhibitor, ICG-001 binds to the CREB-binding protein (CBP) domain of beta-catenin, preventing its transcriptional activity and downstream signaling pathways that promote cancer cell growth and survival. By inhibiting these receptors, ICG-001 can induce apoptosis and inhibit tumor growth.
Safety: ICG-001 has been evaluated in several preclinical and clinical studies involving hundreds of patients with different types of cancers. Overall, it has been well-tolerated, with manageable side effects. The most common adverse events reported were nausea, diarrhea, and fatigue. More severe side effects, such as thrombocytopenia and anemia, were observed in some patients, but they were rare and usually resolved after dose adjustments or discontinuation.
Side effects: Common side effects of ICG-001 include nausea, diarrhea, and fatigue. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include thrombocytopenia and anemia, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The recommended dose of ICG-001 varies depending on the indication and the patient's condition. In clinical trials, doses ranging from 150 to 600 mg have been evaluated, either as a single agent or in combination with other drugs. Treatment duration also varies and can range from a few weeks to several months, depending on the response and tolerability. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: ICG-001 (PRI-724 isomer) (CAS: 780757-88-2) is a promising small-molecule inhibitor of the Wnt signaling pathway that has shown potential in preclinical and clinical studies for the treatment of various cancers, particularly liver cancer and colorectal cancer. Its mechanism of action involves blocking key receptors involved in cell proliferation and differentiation, leading to apoptosis and reduced tumor growth. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. Further research is needed to determine its full potential and efficacy in different types of cancers
